Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:52 2024-02-22 pm EST 5-day change 1st Jan Change
28.98 USD +1.54% Intraday chart for Rocket Pharmaceuticals, Inc. -5.05% -3.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : S&P 500 Futures -2- DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director CI
Rocket Pharmaceuticals Insider Sold Shares Worth $450,646, According to a Recent SEC Filing MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cantor Fitzgerald Initiates Rocket Pharmaceuticals With Overweight Rating, Price Target is $65 MT
Rocket Pharmaceuticals Insider Sold Shares Worth $315,744, According to a Recent SEC Filing MT
Rocket Pharmaceuticals' Biologics License Application for Gene Therapy Accepted by US FDA for Priority Review MT
Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) CI
RTW Biotech's Rocket Pharmaceuticals makes Danon progress AN
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Sector Update: Health Care MT
Top Midday Gainers MT
Rocket Pharmaceuticals, US FDA Agree on Design of Mid-Stage Trial of Genetic Disorder Drug Candidate MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Traders Digest Consumer Inflation Report, Driving Narrow Premarket Losses for US Equity Futures MT
Top Premarket Gainers MT
Chart Rocket Pharmaceuticals, Inc.
More charts
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders. The Company's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe paediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. The Company's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a pediatric heart failure condition. It also has a preclinical AAV-based gene therapy program in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
29 USD
Average target price
49.58 USD
Spread / Average Target
+70.98%
Consensus
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer